---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-039530"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2026-08-20T22:45:15+00:00"
generated_at: "2026-08-21T10:05:36.244627+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Interpace shareholders approve reverse split up to 1-for-10, equity plans, and director slate

## Summary
- Reverse stock split authorized (1:2 to 1:10 ratio, board discretion within 1 yr): 26,180,980 for, 397,262 against.
- Amended & restated certificate of incorporation approved: 24,981,181 for, 246,552 against, 3,625 abstain.
- All five director nominees elected, incl. CEO Thomas W. Burnell (25,095,783 for) and Joseph D. Keegan (24,422,783 for).
- 2026 Equity Incentive Plan approved: 24,887,762 for; 2026 Employee Stock Purchase Plan: 24,580,773 for.
- Say-on-pay passed (24,952,970 for); EisnerAmper LLP ratified as auditor (26,442,760 for).

## SEC filing metadata
- accession: 0001493152-26-039530
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2026-08-20T22:45:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/0001493152-26-039530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-039530
- JSON: https://secwatch.observer/filing/0001493152-26-039530.json
- Plain text: https://secwatch.observer/filing/0001493152-26-039530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.